Astrazeneca boosted as Covid-19 therapies offset vaccine drop

Although the UK pharmaceutical firm saw a drop in vaccine sales, other Covid-19 treatments have fared better, allowing Astrazeneca to raise its revenue guidance for 2022.


Astrazeneca Plc raised its outlook for 2022 revenue as sales of its Covid-19 therapies offset a decline in its coronavirus vaccine.

The UK drugmaker now expects revenues to rise by more than 20% this year, according to a statement Friday that showed its second-quarter earnings beat analysts’ estimates.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs